Aladin (amlodipin besylat) tablets 5 mg. №30

Description

Composition

active ingredient: amlodipine besylate;

1 tablet contains amlodipine besylate – 6.95 mg 13.90 mg (in terms of amlodipine 5 mg or 10 mg)

Excipients: microcrystalline cellulose, anhydrous calcium hydrogen phosphate, sodium starch (type A), magnesium stearate.

Indications

– arterial hypertension.

– chronic stable angina pectoris.

– Vasospastic angina (Prinzmetal’s angina).

Contraindications

– Hypersensitivity to dihydropyridines, amlodipine or any other component of the drug.

– severe arterial hypotension.

– Shock (including cardiogenic shock).

– obstruction of the outflow tract of the left ventricle (for example, severe aortic stenosis).

– Hemodynamically unstable heart failure after acute myocardial infarction.

Dosage and administration

Adults. For the treatment of arterial hypertension and angina pectoris, the initial dose of Aladin®-Farmak is 5 mg 1 time per day. Depending on the patient’s response to therapy, the dose may be increased to a maximum dose of 10 mg once daily.

In patients with angina pectoris, the drug can be used as monotherapy or in combination with other antianginal drugs with nitrate resistance and / or adequate doses of beta-blockers.

There is experience of using the drug in combination with thiazide diuretics, alpha-blockers, beta-blockers or ACE inhibitors in patients with arterial hypertension.

There is no need to select a dose of the drug when used simultaneously with thiazide diuretics, beta-blockers and ACE inhibitors.

Children aged 6 years and older with arterial hypertension. The recommended initial dose of Aladin®-Farmak for this category of patients is 2.5 mg 1 time per day (use amlodipine preparations at the appropriate dosage). If the desired level of blood pressure is not reached within 4 weeks, the dose can be increased to 5 mg per day. The use of the drug at a dose of 5 mg for this category of patients has not been studied.

Elderly patients. There is no need to select a dose for this category of patients. Increasing the dose should be done with caution.

Patients with impaired renal function. It is recommended to use the usual doses of the drug, since changes in the concentration of amlodipine in the blood plasma are not associated with the severity of renal failure. Amlodipine is not excreted by dialysis.

Patients with liver failure. Doses of the drug for use in patients with mild to moderate hepatic insufficiency have not been established, so dose selection should be carried out with caution and start at a low dose (see Section “Peculiarities of use” and “Pharmacological properties. Pharmacokinetics”).

The pharmacokinetics of amlodipine has not been studied in patients with severe hepatic impairment. For patients with severe hepatic impairment, amlodipine should be started at a low dose and gradually increased.